HUE035332T2 - 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors - Google Patents

1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors Download PDF

Info

Publication number
HUE035332T2
HUE035332T2 HUE13703121A HUE13703121A HUE035332T2 HU E035332 T2 HUE035332 T2 HU E035332T2 HU E13703121 A HUE13703121 A HU E13703121A HU E13703121 A HUE13703121 A HU E13703121A HU E035332 T2 HUE035332 T2 HU E035332T2
Authority
HU
Hungary
Prior art keywords
pyrrolo
pyridin
benzyl
pyrazole
amide
Prior art date
Application number
HUE13703121A
Other languages
English (en)
Hungarian (hu)
Inventor
Stephen Stokes
Christoper John Graham
Stuart Christopher Ray
Emma Jayne Stefaniak
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Publication of HUE035332T2 publication Critical patent/HUE035332T2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HUE13703121A 2012-01-30 2013-01-30 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors HUE035332T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1201566.5A GB201201566D0 (en) 2012-01-30 2012-01-30 New chemical compounds

Publications (1)

Publication Number Publication Date
HUE035332T2 true HUE035332T2 (en) 2018-05-02

Family

ID=45876325

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13703121A HUE035332T2 (en) 2012-01-30 2013-01-30 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors

Country Status (21)

Country Link
US (3) US10000481B2 (en:Method)
EP (1) EP2809670B1 (en:Method)
JP (1) JP6199316B2 (en:Method)
CN (4) CN106866658B (en:Method)
AU (1) AU2013213954B2 (en:Method)
BR (1) BR112014018795B1 (en:Method)
CA (1) CA2862940C (en:Method)
DK (1) DK2809670T3 (en:Method)
EA (1) EA026657B1 (en:Method)
ES (1) ES2637340T3 (en:Method)
GB (1) GB201201566D0 (en:Method)
HK (1) HK1200447A1 (en:Method)
HU (1) HUE035332T2 (en:Method)
IL (1) IL233595B (en:Method)
IN (1) IN2014DN06104A (en:Method)
MX (1) MX352927B (en:Method)
NZ (1) NZ627361A (en:Method)
PL (1) PL2809670T3 (en:Method)
PT (1) PT2809670T (en:Method)
WO (1) WO2013114113A1 (en:Method)
ZA (1) ZA201405070B (en:Method)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
JP6370772B2 (ja) * 2012-04-23 2018-08-08 ジェネンテック, インコーポレイテッド 化合物の調製のための中間体及び方法
CA2921956C (en) * 2013-08-22 2021-10-19 Genentech, Inc. Process for preparing (r)-5-bromo-4-(3-amino)piperidin-1-yl)-3-(cyclopropanecarboxamido)-1h-pyrrolo[2,3-b]pyridine
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
US10032914B2 (en) * 2015-10-20 2018-07-24 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device and manufacturing method thereof
EP3269370B1 (en) 2016-02-23 2020-01-08 Taiho Pharmaceutical Co., Ltd. Novel condensed pyrimidine compound or salt thereof
AU2018322286B2 (en) 2017-08-21 2022-03-10 Taiho Pharmaceutical Co., Ltd. Fusion protein of DCTN1 protein with RET protein
WO2020150417A2 (en) 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN111518096B (zh) 2019-02-02 2022-02-11 江苏威凯尔医药科技有限公司 两面神激酶jak家族抑制剂及其制备和应用
US20220281842A1 (en) 2019-08-01 2022-09-08 Integral Biosciences Pvt. Ltd. Heterocyclic compounds as kinase inhibitor and uses thereof
IT202000005527A1 (it) * 2020-03-16 2021-09-16 Univ Degli Studi Di Trento Trattamento terapeutico di cromatinopatie
TW202216685A (zh) * 2020-07-15 2022-05-01 美商Ifm Due有限公司 用於治療與sting活性相關的病狀之化合物及組合物
WO2022015975A1 (en) 2020-07-15 2022-01-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US20230365553A1 (en) * 2020-07-15 2023-11-16 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN117529475A (zh) 2021-01-08 2024-02-06 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的含脲或类似物的杂双环化合物及其化合物
JP2025503675A (ja) * 2022-01-12 2025-02-04 アイエフエム デュー インコーポレイテッド Sting活性に関連する病態を治療するための化合物及び組成物
CN116554170A (zh) * 2023-04-26 2023-08-08 上海大学 4-氟-7-氮杂吲哚的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012976A (en) * 1909-03-25 1911-12-26 Adolf Bordt Adding-machine.
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
CN102786482A (zh) * 2003-11-21 2012-11-21 阿雷生物药品公司 Akt蛋白激酶抑制剂
ES2394759T3 (es) 2008-01-08 2013-02-05 Array Biopharma, Inc. Pirrolopiridinas como inhibidores de quinasa
EA021464B1 (ru) * 2008-01-22 2015-06-30 Вернэлис (Р&Д) Лтд. Производные индол-пиридона, обладающие ингибиторной активностью в отношении киназы 1, содержащая их фармацевтическая композиция и их применение
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
MX2010013606A (es) * 2008-06-11 2010-12-21 Genentech Inc Diazacarbazoles y metodos de uso.
WO2011017142A1 (en) * 2009-08-06 2011-02-10 Merck Patent Gmbh Novel bicyclic urea compounds
WO2011146313A1 (en) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds

Also Published As

Publication number Publication date
JP2015505555A (ja) 2015-02-23
AU2013213954A1 (en) 2014-08-07
CN104203948A (zh) 2014-12-10
BR112014018795A2 (pt) 2017-07-04
MX352927B (es) 2017-12-14
US20180362526A1 (en) 2018-12-20
MX2014009112A (es) 2014-11-10
HK1200447A1 (en) 2015-08-07
US10000481B2 (en) 2018-06-19
WO2013114113A1 (en) 2013-08-08
EA026657B1 (ru) 2017-05-31
DK2809670T3 (en) 2017-08-28
AU2013213954B2 (en) 2016-02-25
IL233595B (en) 2018-05-31
PT2809670T (pt) 2017-08-23
EA201491376A1 (ru) 2015-01-30
CN107011341A (zh) 2017-08-04
NZ627361A (en) 2016-07-29
PL2809670T3 (pl) 2017-10-31
CA2862940A1 (en) 2013-08-08
US20210206762A1 (en) 2021-07-08
EP2809670B1 (en) 2017-05-17
EP2809670A1 (en) 2014-12-10
CN111484493A (zh) 2020-08-04
CN106866658B (zh) 2021-04-27
US10889582B2 (en) 2021-01-12
CA2862940C (en) 2021-09-14
JP6199316B2 (ja) 2017-09-20
IN2014DN06104A (en:Method) 2015-08-14
BR112014018795B1 (pt) 2020-09-29
CN106866658A (zh) 2017-06-20
ES2637340T3 (es) 2017-10-11
ZA201405070B (en) 2016-03-30
GB201201566D0 (en) 2012-03-14
US20150011533A1 (en) 2015-01-08
IL233595A0 (en) 2014-08-31

Similar Documents

Publication Publication Date Title
DK2809670T3 (en) 1H-PYRROLO [2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS
JP7051829B2 (ja) Dnmt1の阻害剤としての置換ピリジン
CN104781255B (zh) 作为trka激酶抑制剂的n‑吡咯烷基、n’‑吡唑基‑脲、硫脲、胍和氰基胍化合物
JP6277121B2 (ja) 置換された縮合三環式化合物、その組成物および医学的応用
CN111601799A (zh) 作为Il-17调节剂的稠合咪唑衍生物
JP2022500368A (ja) 急速進行性線維肉腫ポリペプチドの標的分解のための多環式化合物および方法
ES2461799T3 (es) Derivados de indolil-piridona que tienen actividad inhibidora de la quinasa de control 1
CN113166142B (zh) 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
CN107635986A (zh) 取代的喹喔啉衍生物
CN116710430A (zh) 用于恢复突变p53功能的方法和化合物
CN113613722A (zh) 新型咪唑-吡唑衍生物
WO2023174406A1 (zh) 含氮杂环类衍生物抑制剂、其制备方法和应用
WO2024083208A1 (zh) Kif18a蛋白抑制剂
WO2021121390A1 (zh) 杂环化合物及其药物组合物、制备方法、中间体和应用
WO2021249417A1 (zh) 杂环化合物及其衍生物
CN114981270A (zh) Mll1抑制剂和抗癌剂
HK1240217B (zh) 1h-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途
HK1240217A1 (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
HK1240227A1 (zh) 1h-吡咯并[2,3-b]吡啶衍生物及他们作为激酶抑制剂的用途
HK40025567A (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors